drugset / Trial / NCT00958269

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

NCT00958269

Phase 3 Terminated 360 enrolled Phenomix Forest Laboratories · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of dutogliptin in Type 2 diabetic subjects with moderate or severe renal impairment.

Timeline

Start
2009-08
Primary completion
2011-09
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dutogliptin Small molecule 100 mg
Subject Dutogliptin Small molecule 200 mg
Comparator Sitagliptin Small molecule 25 mg
Comparator Sitagliptin Small molecule 50 mg